Related Experiment Video
Updated: Jul 10, 2026

Kinetic Visualization of Single-Cell Interspecies Bacterial Interactions
Published on: August 5, 2020
Akkermansia muciniphila in cardiovascular diseases: opportunities and challenges
Shihao Li1, Chuanmeng Zhang2, Min Sha2
1The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, China.
Insights
Akkermansia muciniphila (A. muciniphila) shows promise in preventing cardiovascular disease (CVD) by improving gut health and metabolism. However, its effects can be detrimental in certain conditions, necessitating personalized therapeutic strategies.
Area of Science:
- Microbiology
- Cardiovascular Medicine
- Gut Microbiome Research
Background:
- Cardiovascular disease (CVD) is a leading global cause of mortality.
- The gut microbiota's role in cardiovascular health is an emerging area of research.
- Akkermansia muciniphila (A. muciniphila) is a key gut bacterium with potential therapeutic applications.
Purpose of the Study:
- To review the beneficial effects and mechanisms of A. muciniphila in cardiovascular disease (CVD).
- To explore the dual role of A. muciniphila as both protective and potentially harmful in CVD.
- To highlight factors influencing A. muciniphila abundance and its implications for personalized medicine.
Main Methods:
- Literature review of studies investigating A. muciniphila and cardiovascular health.
- Analysis of mechanisms by which A. muciniphila impacts hypertension, atherosclerosis, heart failure, and abdominal aortic aneurysm.
- Examination of factors modulating A. muciniphila abundance, including diet and medication.
Main Results:
- A. muciniphila demonstrates protective effects against various CVDs by enhancing gut barrier function, regulating metabolism, and modulating immune responses.
- Production of beneficial metabolites like short-chain fatty acids by A. muciniphila contributes to its cardioprotective effects.
- Under pathological conditions (e.g., damaged gut barrier, low-fiber diet), A. muciniphila can exhibit detrimental effects, exacerbating inflammation and disease progression.
Conclusions:
- A. muciniphila possesses a "double-edged sword" character in cardiovascular health, with both beneficial and detrimental potential.
- Individual factors such as diet, medication, and baseline gut microbiota composition significantly influence A. muciniphila's impact.
- Further research is needed to optimize A. muciniphila's clinical application in CVD therapy, focusing on strain specificity, dosage, and delivery systems.
Abstract:
Cardiovascular disease (CVD) is one of the leading causes of death worldwide and poses a severe threat to human health. Recent years have witnessed a growing interest in how the gut microbiota regulates the cardiovascular system. Akkermansia muciniphila (A. muciniphila), a key constituent of this community, has become a focus of research on CVD prevention owing to its critical role in maintaining gut homeostasis, modulating metabolism, and regulating immunity. This review details the beneficial effects and mechanisms of action of A. muciniphila in CVD. A. muciniphila protects against conditions such as hypertension, atherosclerosis, heart failure, and abdominal aortic aneurysm by repairing the gut barrier, balancing glucose and lipid metabolism, regulating immune-inflammatory responses, and producing protective metabolites such as short-chain fatty acids. However, in pathological states, such as a damaged gut barrier or low-fiber diets, A. muciniphila can over-proliferate, accelerate mucus breakdown, and exacerbate inflammation and disease progression-revealing a "double-edged sword" character. Furthermore, diet, medications, and an individual's baseline gut microbiota directly modulate their abundance, underscoring the need for personalized approaches. Future studies should focus on clarifying strain differences, establishing safe dosing, and optimizing delivery systems to advance the clinical application of A. muciniphila in CVD therapy.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Endocarditis III: Medical Management
Microbiota of the Respiratory Tract
Microbial Corrosion
Endocarditis I: Introduction
Dysbiosis of the Gut Microbiota
